A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mrinal M. Gounder, Todd Michael Bauer, Gary K. Schwartz, Tyler Masters, Richard D. Carvajal, Saeheum Song, Prasanna Kumar, Roohi Gajee, Oleg Zernovak, Michael M. Rosen, Jarema Peter Kochan, Shuquan Chen, David Michael Hyman, Sugun Gokmen, Funda Meric-Bernstam, Patricia LoRusso, Neeta Somaiah, Amy M. Weise, David S. Hong
Institutions: Memorial Sloan Kettering Cancer Center, Tennessee Oncology, NewYork–Presbyterian Hospital, Columbia University Irving Medical Center, Daiichi Sankyo (United States), Daiichi-Sankyo (Japan), The University of Texas MD Anderson Cancer Center, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, Wayne State University, The Barbara Ann Karmanos Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2797465271